References
- Coates A, Abraham S, Kaye SB, et al. On the receiving end: patients perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203–208.
- White L, Daly SA, McKenna CJ, et al. A comparison of oral ondensatron syrup or intravenous on-densetron loading dose regimes given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly ematogenic chemotherapy. Pediats Hematol Oncol 2000;17:445–455.
- Cohen IJ, Zahavi N, Buchwald I, et al. Oral ondansetron: an ambulatory complement to intravenous ondansetron in the control of chemotherapy-induced nausea and vomiting in children. Pediatr Hematol Oncol. 1995;12:67–72.
- Cohen IJ. Control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol. 1999;16:87–88.
- Shoji A, Toda M, Suzuki K, et al. Insufficient effectiveness of 5-hydroxytryptamine-3 receptor antag-onists due to oral morphine administration in patients with cisplatin-induced emesis. J Clin Oncol 199917:1926-1930.
- Hesketh PJ, Gralla RJ, Webb RT, et al. Randomised phase 2 study of the neurokinin 1 receptor antag-onist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol. 1999;17:338–343.